Vir Biotechnology Correlations
VIR Stock | USD 7.12 0.17 2.45% |
The current 90-days correlation between Vir Biotechnology and CureVac NV is 0.3 (i.e., Weak diversification). The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Vir Biotechnology Correlation With Market
Very weak diversification
The correlation between Vir Biotechnology and DJI is 0.46 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Vir Biotechnology and DJI in the same portfolio, assuming nothing else is changed.
Vir |
Moving together with Vir Stock
Moving against Vir Stock
0.57 | PG | Procter Gamble | PairCorr |
0.39 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
0.33 | HYMTF | Hyundai Motor | PairCorr |
0.32 | WF | Woori Financial Group | PairCorr |
0.32 | TLK | Telkom Indonesia Tbk | PairCorr |
0.32 | KO | Coca Cola Aggressive Push | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Vir Stock performing well and Vir Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Vir Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
CVAC | 2.34 | (0.38) | 0.00 | (0.20) | 0.00 | 4.45 | 16.27 | |||
RETA | 2.22 | 0.21 | 0.02 | (1.50) | 3.31 | 5.24 | 28.80 | |||
KRYS | 1.82 | (0.22) | 0.00 | (0.02) | 0.00 | 4.45 | 12.05 | |||
PPCB | 8.09 | 0.37 | 0.01 | (0.73) | 10.58 | 33.33 | 58.33 | |||
ISEE | 1.24 | 0.63 | 0.43 | 4.57 | 0.25 | 2.45 | 18.29 | |||
BPMC | 1.84 | (0.12) | (0.03) | 0.03 | 2.61 | 4.90 | 14.28 | |||
AMLX | 4.24 | 1.32 | 0.27 | 1.26 | 4.02 | 10.06 | 33.56 | |||
KRTX | 1.44 | 0.08 | (0.04) | (0.15) | 1.67 | 3.38 | 10.01 | |||
DAWN | 2.10 | (0.08) | (0.03) | 0.03 | 2.72 | 3.84 | 11.44 | |||
VKTX | 3.51 | (0.37) | 0.00 | (0.13) | 0.00 | 6.24 | 34.61 |
Vir Biotechnology Corporate Management
Vanina JD | General VP | Profile | |
Klaus Frueh | CoFounder Advisor | Profile | |
Lawrence MD | CoFounder Advisor | Profile | |
Johanna FriedlNaderer | Ex COO | Profile | |
George Scangos | CEO Pres | Profile | |
Louis MD | CoFounder Advisor | Profile |